In vitro binding experiments with a Valerian, Hops and their fixed combination extract (Ze91019) to selected central nervous system receptors

被引:62
作者
Abourashed, EA
Koetter, U
Brattström, A
机构
[1] King Saud Univ, Coll Pharm, Dept Pharmacognosy, Riyadh 11451, Saudi Arabia
[2] GlaxoSmithKline Consumer Healthcare, Parsippany, NJ USA
[3] Zeller Med AG, Romanshorn, Switzerland
关键词
Valeriana officinalis; Humulus lupulus; Valerian-hops extract; receptor binding; CNS sedative activity;
D O I
10.1016/j.phymed.2004.03.005
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
The fixed valerian-hops extract combination Ze91019 is used as a sleep aid. Although its exact mechanism of action is not well understood, earlier studies indicate that the CNS effect of valerian might occur through interaction with the GABA, melatonin and/or the adenosine systems in the brain. The use of hops in sleep remedies, however, is mainly based on traditional use and scarce scientific information. In this report, the binding of Ze91019, and the component valerian and hops extracts within, was tested on 14 subtypes of five classes of central receptors (dopamine, serotonin, melatonin, MCH and neuropeptide-Y). Binding affinities could be demonstrated at some of the screened melatonin (ML1 and ML2) and serotonin (5-HT4e, 5-HT6 and 5-HT7) receptor subtypes. (C) 2004 Published by Elsevier GmbH.
引用
收藏
页码:633 / 638
页数:6
相关论文
共 22 条
[2]  
Bos R., 1997, ADVERS EFF HERB DRUG, V3, P165
[3]  
Bravo L, 1974, Boll Chim Farm, V113, P310
[4]   Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1 [J].
Chambers, J ;
Ames, RS ;
Bergsma, D ;
Muir, A ;
Fitzgerald, LR ;
Hervieu, G ;
Dytko, GM ;
Foley, JJ ;
Martin, J ;
Liu, WS ;
Park, J ;
Ellis, C ;
Ganguly, S ;
Konchar, S ;
Cluderay, J ;
Leslie, R ;
Wilson, S ;
Sarau, HM .
NATURE, 1999, 400 (6741) :261-265
[5]  
FAUTECK JD, 1996, PHYTOMEDICINE, V3, P76
[6]   [LEU31,PRO34]NEUROPEPTIDE-Y - A SPECIFIC Y-1 RECEPTOR AGONIST [J].
FUHLENDORFF, J ;
GETHER, U ;
AAKERLUND, L ;
LANGELANDJOHANSEN, N ;
THOGERSEN, H ;
MELBERG, SG ;
OLSEN, UB ;
THASTRUP, O ;
SCHWARTZ, TW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (01) :182-186
[7]  
GRAFF A, 1999, ANAL QUALITY CONTROL
[8]   CLONING OF THE CDNA AND GENE FOR A HUMAN D2-DOPAMINE RECEPTOR [J].
GRANDY, DK ;
MARCHIONNI, MA ;
MAKAM, H ;
STOFKO, RE ;
ALFANO, M ;
FROTHINGHAM, L ;
FISCHER, JB ;
BURKEHOWIE, KJ ;
BUNZOW, JR ;
SERVER, AC ;
CIVELLI, O .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (24) :9762-9766
[9]   CHARACTERIZATION OF THE HUMAN DOPAMINE D-3 RECEPTOR EXPRESSED IN TRANSFECTED CELL-LINES [J].
MACKENZIE, RG ;
VANLEEUWEN, D ;
PUGSLEY, TA ;
SHIH, YH ;
DEMATTOS, S ;
TANG, L ;
TODD, RD ;
OMALLEY, KL .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1994, 266 (01) :79-85
[10]   Isolation of the serotoninergic 5-HT4(e) receptor from human heart and comparative analysis of its pharmacological profile in C6-glial and CHO cell lines [J].
Mialet, J ;
Berque-Bestel, I ;
Eftekhari, P ;
Gastineau, M ;
Giner, M ;
Dahmoune, Y ;
Donzeau-Gouge, P ;
Hoebeke, J ;
Langlois, M ;
Sicsic, S ;
Fischmeister, R ;
Lezoualc'h, F .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (04) :771-781